Nurix Therapeutics Q1 FY2024 revenue $16.6M, net loss $41.5M; Gilead collaboration extended

Nurix Therapeutics, Inc.

2024-Q1 EPS reported -$0.76 revenue$16,585,000

Revenue $16.6M (up 31% YoY); net loss $41.5M ($0.76/sh) vs $40.7M ($0.75/sh) prior year.
Cash $254.3M vs $295.3M at Nov 30, 2023; R&D spend $50.0M (up 9% YoY).
Gilead extended collaboration by 2 years, paying $15M extension fee; total potential milestones up to $1.7B.
Sanofi extended STAT6 program; Nurix expects to nominate clinical candidate in 12 months.
FDA lifted partial clinical hold on NX-2127 (BTK degrader) in March 2024; enrollment to reinitiate.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.96

Nurix Therapeutics, Inc. reported financial results for first quarter ended February 29, 2024.

Period: first quarter ended February 29, 2024
Result: reported results

Exact text from the filing

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today reported financial results for the first quarter ended February 29, 2024, and provided a corporate update.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

Nurix Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001549595-24-000048

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.